Connect with us

News

NHS approves new treatment for advanced womb cancer

The combination has been shown to stimulate the body’s immune system and kill off cancer cell growth

Published

on

Hundreds of women with advanced womb cancer in England are to be offered a new “lifeline” option, as the NHS rolls out a new combination therapy that could halt the progression of the disease.

The NHS has agreed landmark commercial deals for two drugs from different manufacturers, which will be used in combination to treat advanced endometrial cancer in between 500 and 750 women each year.

Clinical trials have shown that pembrolizumab and lenvatinib used together can double the time taken for cancer to progress compared with the existing chemotherapy treatment, from just over three and half months to more than seven months.

In the trial, overall survival was also significantly longer for patients taking the combination therapy compared to existing chemotherapy treatments, with those taking pembrolizumab and lenvatinib living on average almost 19 months compared just under 12 months on existing chemotherapy.

Set for approval today by the National Institute for Health and Care Excellence (NICE), the combination has been shown to stimulate the body’s immune system and kill off cancer cell growth.

As part of the combination treatment, pembrolizumab is delivered intravenously every three or six weeks while lenvatinib is two pills taken once a day.

Currently, patients undergo chemotherapy treatment every three weeks, but unlike with chemotherapy, there is a far less significant risk of hair loss as a side effect of the new combination treatment.

Around 9,400 women are diagnosed with cancer in the womb every year, making it the fourth most common cancer in UK women.

While the treatment was initially rejected in draft guidance by NICE on the grounds of cost-effectiveness, the NHS has been able to use its commercial capabilities to negotiate a deal with the manufacturers, allowing the treatment to be made available to patients.

“It is fantastic news that this innovative combination therapy can now offer a new lifeline to hundreds of women living with advanced endometrial cancer, giving hope of precious extra time to live with a better quality of life,” said NHS national cancer director Professor Peter Johnson.

“Now in its 75th year, the NHS is leading the world in making the latest treatments available through its unique commercial capabilities and commitment to innovation on behalf of patients and their families across the country.”

Grace Teeling, a 33-year-old from Bristol who was diagnosed with advanced stage three womb cancer in 2019, said: “I have been incredibly fortunate to receive treatment for the past two years and I had a really good response, which means there is currently no evidence of cancer on my recent scans,” she said.

“It has enabled me to thrive despite having an advanced and incurable cancer diagnosis.

“I am able to work, travel, socialise and exercise, including paddleboarding, which I may not have been able to do on chemotherapy. I am delighted others will now be able to access this treatment as I don’t think I would be alive today if I hadn’t.”

Professor Emma Crosbie, chair of trustees of Peaches Womb Cancer Trust, said: “This innovative new treatment regimen will benefit patients with advanced or recurrent endometrial cancer, who currently have very few effective anti-cancer treatments available to them.

“Every year, many people are facing a diagnosis of advanced or recurrent womb cancer, and the frightening reality of very few treatment options that can improve their survival and quality of life.

“Those affected by womb cancer deserve more treatment options, but we hope that this is just the first step towards wider availability of more effective treatment options for those affected by this devastating cancer.”

David Long, head of oncology at MSD UK, which manufactures pembrolzimab, said: “Endometrial cancer is one of the few cancers with rising incidence and mortality, and historically there has been limited treatment options for people with advanced stages of the disease.

“We are therefore very pleased that a new treatment option has been made available to patients which will help address this unmet need.

“We are proud to have worked alongside Eisai, NICE and NHS England to ensure patients can access this treatment.”

The combination treatment will be funded by the NHS and will be offered to all eligible women who have previously received treatment for advanced or recurrent endometrial cancer.

Pregnancy

Pregnant women may reduce key health risk through more light exercise, study finds

Published

on

Light exercise and less sitting may reduce pregnant women’s risk of serious blood pressure complications, according to a new study.

Researchers have proposed a daily activity and sleep guide that they say was linked to a nearly 30 per cent lower risk of hypertensive disorders of pregnancy.

The suggested pattern includes fewer than eight hours of sedentary time, at least seven hours of light physical activity, around 22 minutes of more intense activity and nearly nine hours of sleep.

The University of Iowa-led study examined the daily behaviours of 470 pregnant women across all stages of pregnancy.

Participants wore monitors that measured physical activity over 24-hour periods and recorded how long they spent asleep.

Hypertensive disorders of pregnancy include chronic high blood pressure, gestational hypertension and pre-eclampsia.

Gestational hypertension is high blood pressure that develops during pregnancy, while pre-eclampsia is a potentially serious condition involving high blood pressure and signs that organs may be affected.

Sedentary behaviour means being mostly inactive, such as sitting or lying down.

Light physical activity can include casual walking, moving around the home or standing.

Moderate to vigorous activity includes movement such as brisk walking, where breathing and heart rate increase.

Kara Whitaker, associate professor in the department of health, sport, and human physiology at Iowa and corresponding author of the study, said: “We are identifying the optimal composition of movement behaviours across the day associated with the lowest risk of developing HDP and the most improved health outcomes.

“This blueprint holds for each and every trimester of pregnancy.”

Study participants were enrolled at sites in Iowa City, Pittsburgh and Morgantown, West Virginia.

The women wore activity and sleep monitors for at least one week during each trimester of pregnancy.

Four in five participants were non-Hispanic white and nearly a quarter lived in rural areas.

The data showed a steep rise in risk among pregnant women who were sedentary for more than 10 hours a day.

Women who increased light physical activity to at least four hours a day reduced their risk of hypertensive disorders of pregnancy to 15 per cent from 30 per cent.

Whitaker said: “Just moving around more seems to have significant health benefits.

“And I think it also may be a more feasible target for women who are pregnant who are not exercising regularly.”

The researchers said they were surprised that longer durations of moderate to vigorous physical activity did not appear to provide additional benefit.

Sleep beyond a certain duration also did not appear to bring major further benefits.

Whitaker said: “Through this study, we are providing evidence that reducing sedentary behaviour and engaging in light physical activity are important, and maybe more important, when it comes to pregnancy and health.”

The findings may be relevant beyond pregnancy because clinical research has shown that women who develop hypertensive disorders of pregnancy are more than twice as likely to develop heart disease later in life.

Cardiovascular disease includes conditions affecting the heart and blood vessels, such as heart disease and stroke.

Whitaker said: “We know that cardiovascular disease is the number one killer of women, and if we can intervene in pregnancy and prevent women from developing a hypertensive disorder of pregnancy, we are putting them on a better trajectory, away from cardiovascular disease and toward more optimal cardiovascular health.”

The study was published online on June 10.

A second study, published online on May 27, looked more closely at the ratio and type of sedentary behaviour and light physical activity linked to a lower risk of hypertensive disorders of pregnancy.

Whitaker is a lead co-author on that study.

Co-authors in the June 10 study include Alex Crisp, Jaemyung Kim, Karina Smith, Donna Santillan, Mark Santillan and Bridget Zimmerman, from Iowa; Jacob Gallagher, from Iowa State University; Melissa Jones, from Oakland University in Michigan; Bethany Barone Gibbs, Katrina Wilhite, Alexis Thrower and Iqra Sheikh, from West Virginia University; and Sabera Rahman, Janet Catov, Christopher Kline and Maisa Feghali, from the University of Pittsburgh.

The National Institutes of Health, the University of Iowa Institute for Clinical and Translational Science, the University of Pittsburgh Clinical and Translational Science Institute and the West Virginia Clinical and Translational Science Institute funded the research.

Continue Reading

News

Femtech World Awards 2026: Winners revealed

Published

on

We are excited to reveal the winners of the third annual Femtech World Awards.

The winners were announced at a virtual event this afternoon attended by shortlisted companies, along with sponsors and judges.

The event welcomed guests from the UK, Europe, Asia, Africa and North America.

Thank you to all 174 entries, as well as the sponsors for making the event possible.

See you in 2027!

Femtech World Awards 2026 Winners

Winner:

Shortlisted:

IVI RMA x Juno Genetics

Natural Cycles

Winner:

Highly commended:

U-Ploid

Shortlisted:

Hello Inside

Winner:

WISE HF, led by Prof. Mary Ryder

Highly commended:

Cardiac College for Women

Shortlisted:

Hyvelle Ferguson-Davis

CognitiveCare

Winner:

Highly commended:

Youterus

Shortlisted:

ŌURA

Winner:

Shortlisted:

LeanShield by ParrotPal Group

Perigen

Winner:

Shortlisted:

Body Moody

Looop

Winner:

Shortlisted:

Owning Your Menopause

Womeno

Winner:

Shortlisted:

The Blue Box

Celbrea

Winner:

Shortlisted:

HealCycle

Mor

Winner:

Shortlisted:

HRC Fertility

Mira

Continue Reading

Motherhood

Expectations about sleep affect postpartum sleep quality, study finds

Published

on

Pregnant women’s expectations about postpartum sleep may predict sleep quality after birth, outweighing prior sleep and psychiatric history, a study suggests.

The findings suggest attitudes and beliefs about sleep during pregnancy could be a modifiable risk factor for postpartum sleep concerns.

They also indicate that, among women expecting the poorest sleep, higher postpartum anxiety may further worsen sleep quality.

Sammy Dhaliwal, lead author is clinical health psychologist and research fellow in the department of obstetrics and gynaecology at the Perelman School of Medicine at the University of Pennsylvania.

Dhaliwal said: “Most pregnant women in our sample anticipated poor postpartum sleep before it occurred, and it was striking that those expectations predicted worse sleep outcomes even after accounting for factors such as prior sleep disorders, psychiatric history, and number of previous births.

“This suggests that attitudes and beliefs about sleep during pregnancy may represent a modifiable target for early intervention before postpartum sleep problems emerge.”

Sleep disturbance affects an estimated 60 to 80 per cent of postpartum women and is linked to a higher risk of depression and anxiety.

Researchers said it is often regarded as an expected part of life after childbirth rather than a health issue that may be addressed earlier.

The study enrolled 432 pregnant women at about 24 weeks of gestation, meaning around 24 weeks into pregnancy.

Participants completed measures of their expectations about postpartum sleep, current sleep quality using the Pittsburgh Sleep Quality Index, and mood using validated depression and anxiety scales.

Assessments were repeated at six, 12 and 24 weeks postpartum.

A subset of 49 women also wore wrist actigraphy devices at six to eight weeks postpartum.

Actigraphy uses a wearable device, similar to a watch, to estimate sleep and wake patterns based on movement.

The results showed that 70 per cent of pregnant women, or 301 of 432 participants, expected poor sleep in the postpartum period.

Researchers found that predicted sleep disruption during pregnancy was a significant predictor of postpartum sleep concerns.

Among first-time pregnant women without prior health concerns, those who expected greater sleep disturbance had significantly more disrupted sleep after birth, measured by both actigraphy and self-report.

Among women who expected the worst sleep quality, higher postpartum anxiety significantly worsened both measured sleep and self-reported sleep, independent of anxiety levels during pregnancy.

Dhaliwal said the findings point to two possible areas for intervention: addressing sleep-related beliefs during pregnancy and treating postpartum anxiety.

Dhaliwal said: “Postpartum sleep disruption is often treated only after problems develop, but our findings suggest there may be an opportunity to intervene earlier during pregnancy.

“Addressing sleep-related beliefs and postpartum anxiety during prenatal and postpartum care may help improve sleep and emotional well-being in new mothers.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.